Methods for enhancing hematopoietic stem/progenitor cell engraftment

Patent metadata

Field	Value
Publication number	US-10092599-B2
Application number	US-201514706560-A
Country	US
Kind code	B2
Filing date	May 7, 2015
Priority date	Feb 3, 2009
Publication date	Oct 9, 2018
Grant date	Oct 9, 2018

Abstract

Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.

First claim

The invention claimed is:

1. A method for enhancing hematopoietic cell engraftment in a subject, the method comprising:
(a) contacting a population of hematopoietic cells with a compound selected from the group consisting of: 1,2-didecanoyl-glycerol (10:0), 1-hexadecyl-2arachidonoyl glycerol, 6-formylindolo [3,2-B] carbazole, anandamide, carbacyclin, carbamyl PAF (C-PAF), Prostaglandin B2, 5-hydroxydecanoate, and 1,2-dioctanoyl-sn-glycerol (DOG); and
(b) administering treated cells from step (a) to a subject in need thereof, wherein the engraftment of the hematopoietic cells treated with the compound is increased compared to engraftment of a population of untreated hematopoietic cells.

2. The method of claim 1 , wherein said population of hematopoietic cells is derived from cord blood.

3. The method of claim 1 , wherein said population of hematopoietic cells is derived from bone marrow.

4. The method of claim 1 , wherein said population of hematopoietic cells is derived from blood.

5. The method of claim 1 , wherein said population of hematopoietic cells are isolated cells.

6. The method of claim 1 , wherein said population of hematopoietic cells is a heterogeneous population of cells.

7. The method of claim 1 , wherein said contacting step is performed on ex vivo cells in culture.

8. The method of claim 1 , wherein said subject is a human subject.

9. The method of claim 1 , wherein said hematopoietic cells are hematopoietic stem cells.

10. The method of claim 1 , wherein said hematopoietic cells are hematopoietic progenitor cells.

11. The method of claim 1 , wherein said population of hematopoietic cells is a homogeneous population of cells.

12. The method of claim 1 , further comprising administering at least one additional agent that enhances hematopoietic stem cell engraftment.

13. A method for enhancing hematopoietic cell engraftment in a subject comprising: administering to a subject following transplantation of a population of hematopoietic cells, a therapeutically effective amount of a compound selected from the group consisting of: 1,2-didecanoyl-glycerol (10:0), 1-hexadecyl-2arachidonoyl glycerol, 6-formylindolo [3,2-B] carbazole, anandamide, carbacyclin, carbamyl PAF (C-PAF), Prostaglandin B2, 5-hydroxydecanoate, and 1,2-dioctanoyl-sn-glycerol (DOG); and
wherein the level of engraftment of the hematopoietic cells in the subject treated with the compound is increased compared to engraftment of a population of hematopoietic cells in an untreated subject.

14. The method of claim 13 , wherein the population of hematopoietic cells is derived from a source selected from the group consisting of cord blood, bone marrow, and blood.

15. The method of claim 13 , wherein the population of hematopoietic cells is a heterogeneous or homogeneous population of cells.

16. The method of claim 13 , wherein the subject is a human subject.

17. The method of claim 13 , wherein the hematopoietic cells are hematopoietic stem cells.

18. The method of claim 13 , wherein the hematopoietic cells are hematopoietic progenitor cells.

19. The method of claim 13 , wherein the compound selected from the group consisting of: 1,2-didecanoyl-glycerol (10:0), 1-hexadecyl-2arachidonoyl glycerol, 6-formylindolo [3,2-B] carbazole, anandamide, carbacyclin, carbamyl PAF (C-PAF), 5-hydroxydecanoate, and 1,2-dioctanoyl-sn-glycerol (DOG).

20. The method of claim 1 , wherein the compound selected from the group consisting of: 1,2-didecanoyl-glycerol (10:0), 1-hexadecyl-2arachidonoyl glycerol, 6-formylindolo [3,2-B] carbazole, anandamide, carbacyclin, carbamyl PAF (C-PAF), 5-hydroxydecanoate, and 1,2-dioctanoyl-sn-glycerol (DOG).

Assignees

• Childrens Medical Center

Inventors

• Zon Leonard I
• Li Pulin

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K31/23

  of acids having a carboxyl group bound to a chain of seven or more carbon atoms · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• A61K31/336

  having three-membered rings, e.g. oxirane, fumagillin · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title